Related Experiment Video

Updated: Aug 19, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

The potential antidepressant tiflucarbine down-regulates beta-adrenoceptors in rat brain

B H Schmidt, J E Schultz

    European Journal of Pharmacology
    |October 14, 1986
    PubMed

    Insights

    Tiflucarbine, a potential antidepressant, reduced noradrenaline (NA) responses and beta-adrenoceptor binding sites in rat brains. This effect was linked to phosphodiesterase inhibition and is reversible, supporting its antidepressant properties.

    Area of Science:

    • Neuropharmacology
    • Molecular Biology

    Background:

    • Subchronic administration of the potential antidepressant tiflucarbine impacts central nervous system signaling pathways.
    • Noradrenaline (NA) pathways are critical targets for antidepressant drug development.

    Purpose of the Study:

    • To investigate the molecular mechanisms underlying tiflucarbine's effects on the noradrenergic system and cAMP signaling in rat cerebral cortex.
    • To elucidate the role of phosphodiesterase and calmodulin in tiflucarbine's action.

    Main Methods:

    • Subchronic treatment of rats with varying doses of tiflucarbine.
    • Measurement of noradrenaline (NA) responses in the cAMP system.
    • Assessment of dihydroalprenolol binding sites in cerebral cortical membranes.
    • Determination of calmodulin (CaM)-dependent phosphodiesterase activity.
    • Inhibition studies of CaM-phosphodiesterase interaction.
    • Adrenergic denervation using 6-hydroxydopamine (6-OHDA).

    Main Results:

    • Tiflucarbine dose-dependently down-regulated NA responses and decreased beta-adrenoceptor binding sites (ED50 = 6 mg/kg).
    • Treatment for 9 days resulted in reversible effects upon discontinuation.
    • Tiflucarbine increased soluble CaM-dependent phosphodiesterase activity by binding to CaM and inhibiting its interaction with the enzyme.
    • 6-OHDA-induced adrenergic denervation prevented both beta-adrenoceptor down-regulation and phosphodiesterase activity increase.

    Conclusions:

    • Tiflucarbine's antidepressant effects may stem from a synergistic interaction between presynaptic phosphodiesterase inhibition and NA reuptake blockade.
    • The observed beta-adrenoceptor down-regulation is mediated by the drug's impact on the noradrenergic system and phosphodiesterase activity.

    More Related Videos

    Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model08:15

    Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

    Published on: June 6, 2025

    Developing a Rat Model for Bipolar Disorder04:42

    Developing a Rat Model for Bipolar Disorder

    Published on: May 2, 2025

    Related Concept Videos

    G-protein Coupled Receptors01:21

    G-protein Coupled Receptors

    G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
    Desensitization and Tachyphylaxis01:20

    Desensitization and Tachyphylaxis

    Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
    Several...
    Drugs Affecting Neurotransmitter Release or Uptake01:21

    Drugs Affecting Neurotransmitter Release or Uptake

    Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
    Antidepressant Drugs: Overview01:25

    Antidepressant Drugs: Overview

    Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
    Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

    Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

    Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
    Antidepressant Drugs: MAOIs and Other Agents01:23

    Antidepressant Drugs: MAOIs and Other Agents

    Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...